Timo Minssen, Professor of Law, Jur. Dr., LL.Lic., LL.M., M.I.C.L.
(En anglais seulement)
Timo Minssen is Professor of Law at the University of Copenhagen (UCPH) and the Founding Director of UCPH's Center for Advanced Studies in Biomedical Innovation Law (CeBIL). He specializes in the interface of Intellectual Property, Competition and Regulatory Law with a special focus on new technologies in the health & life sciences, such as AI and big data-driven precision medicine. His studies involve a plethora of legal issues emerging in the lifecycle of biotechnological and medical products and processes - from the regulation of research and incentives for innovation to technology transfer and commercialization.
At UCPH he had lead several large interdisciplinary research projects in synthetic biology, precision medicine and research infrastructures. At present, he is the principal investigator and grant holder of a large research program in biomedical innovation law, funded by the Novo Nordisk Foundation. Anchored in Copenhagen it involves close collaboration with international core partners, such as Harvard Law School, Harvard Medical School, as well as the Universities of Cambridge and Michigan. Timo has also been the legal expert advisory board member of EU Commission studies of the pharmaceutical sector. He is the steering committee member of the Danish Association for the Protection of Industrial Property and scientific advisory board member of the Copenhagen Centre for Regulatory Sciences (CORS), where he works inter alia with the protection and regulation of biologics and biosimilars.
Timo holds a German law degree from the University of Göttingen, as well as biotech & IP -related LL.M. M.I.C.L., LL.Lic. and LL.D. degrees from Lund & Uppsala University. He has been Visiting Research Fellow at the Universities of Cambridge & Oxford, Harvard Law School, Chicago-Kent College of Law, and at the Max Planck Institute for Innovation & Competition. Moreover, he was trained in the German Court system and at the European Patent Office.